Literature DB >> 7966113

Tablet and insulin therapy in type 2 diabetes in the elderly.

A H Barnett1.   

Abstract

There are a range of therapeutic options available for the management of type 2 diabetes in the elderly. Diet remains the mainstay of treatment although this must be realistic. If diet alone is unsuccessful then, for most patients, short-acting sulphonylurea agents are the treatment of choice. Second line agents include the biguanide, metformin, or an alpha-glucosidase inhibitor. A significant proportion of type 2 diabetic patients will, however, eventually require insulin to alleviate symptoms of poor control and improve glycaemia. In this article I discuss the therapeutic options available for diabetic management in the elderly, with particular emphasis on the pros and cons of insulin treatment.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7966113      PMCID: PMC1294855     

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   5.344


  14 in total

1.  Insulin therapy in the elderly type 2 diabetic patient.

Authors:  W Berger
Journal:  Diabetes Res Clin Pract       Date:  1988       Impact factor: 5.602

Review 2.  Relation of diabetic control to development of microvascular complications.

Authors:  G Tchobroutsky
Journal:  Diabetologia       Date:  1978-09       Impact factor: 10.122

Review 3.  Insulin use in NIDDM.

Authors:  S Genuth
Journal:  Diabetes Care       Date:  1990-12       Impact factor: 19.112

4.  Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus.

Authors:  R Prager; G Schernthaner; H Graf
Journal:  Diabete Metab       Date:  1986-12

5.  Blood glucose concentrations and progression of diabetic retinopathy: the seven year results of the Oslo study.

Authors:  O Brinchmann-Hansen; K Dahl-Jørgensen; L Sandvik; K F Hanssen
Journal:  BMJ       Date:  1992-01-04

6.  Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years.

Authors:  P Reichard; B Berglund; A Britz; I Cars; B Y Nilsson; U Rosenqvist
Journal:  J Intern Med       Date:  1991-08       Impact factor: 8.989

7.  Sulphonylurea therapy doubles B-cell response to glucose in type 2 diabetic patients.

Authors:  J P Hosker; M A Burnett; E G Davies; E A Harris; R C Turner
Journal:  Diabetologia       Date:  1985-11       Impact factor: 10.122

8.  Metformin and the sulphonylureas: the comparative risk.

Authors:  I W Campbell
Journal:  Horm Metab Res Suppl       Date:  1985

9.  Treatment of streptozotocin-diabetic rats with metformin restores the ability of insulin to inhibit adenylate cyclase activity and demonstrates that insulin does not exert this action through the inhibitory guanine nucleotide regulatory protein Gi.

Authors:  D Gawler; G Milligan; M D Houslay
Journal:  Biochem J       Date:  1988-01-15       Impact factor: 3.857

10.  Initiation of insulin treatment after 70 years of age: patient status 2 years later.

Authors:  F Elgrably; D Costagliola; A J Chwalow; P Varenne; G Slama; G Tchobroutsky
Journal:  Diabet Med       Date:  1991-10       Impact factor: 4.359

View more
  1 in total

1.  Factors associated with dietary diversity score among individuals with type 2 diabetes mellitus.

Authors:  Kee Fong Tiew; Yoke Mun Chan; Munn Sann Lye; Seng Cheong Loke
Journal:  J Health Popul Nutr       Date:  2014-12       Impact factor: 2.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.